Biotech Values

[rfj1862]

I think you all are assuming that the biosimilars will be hugely less expensive than the branded treatments. They won't, so I don't expect Humira sales will take the kind of hit small molecules do when they go generic.

There are also very significant questions as to whether "biosimilars" are really all that similar. I think these concerns are justified, unlike the argument that Pfizer's small molecule is somehow better than Teva's small molecule.